It has been confirmed that the inhibition of the PI3K/Akt/mTOR signaling pathway has exhibited encouraging outcomes in various types of cancer, especially hematological malignancies, and might be a potential therapeutic approach for T-ALL [44,45]. The gene discussed is MTOR; the disease is cancer.